✦ LIBER ✦

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

✍ Scribed by Advani, Anjali S.; McDonough, Shannon; Coutre, Steven; Wood, Brent; Radich, Jerald; Mims, Martha; O'Donnell, Margaret; Elkins, Stephanie; Becker, Michael; Othus, Megan; Appelbaum, Frederick R.

Book ID: 124097572
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 78 KB
Volume: 165
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12778

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Southwest Oncology Group Study S0530: a

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

✍ Anjali S. Advani; Holly M. Gundacker; Olga Sala-Torra; Jerald P. Radich; Raymond 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Inotuzumab ozogamicin, an anti-CD22–cale

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

✍ Hagop Kantarjian; Deborah Thomas; Jeffrey Jorgensen; Elias Jabbour; Partow Kebri 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 255 KB

Phase I/II trial of clofarabine and cyta

Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group

✍ Cooper, Todd M.; Razzouk, Bassem I.; Gerbing, Robert; Alonzo, Todd A.; Adlard, K 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB

Phase 2 trial of rituximab plus hyper-CV

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

✍ Michael Wang; Luis Fayad; Fernando Cabanillas; Fredrick Hagemeister; Peter McLau 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

## Abstract ## BACKGROUND. Relapsed or refractory mantle cell lymphoma has a very poor prognosis. The authors evaluated the response rates and survival times of patients treated with an intense regimen known to be effective against untreated aggressive mantle cell lymphoma: rituximab plus hyper‐CV

Phase I/II evaluation of Pentostatin (2′

Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia

✍ S.A. Johnson; D. Catovsky; J.A. Child; A.C. Newland; D.W. Milligan; R. Janmohame 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 47 KB

A phase II trial of high-dose imatinib m

A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial

✍ Patrice Chevallier; Mathilde Hunault-Berger; Fabrice Larosa; Charles Dauriac; Ri 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 101 KB